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Introduction {#s1}
============

In the last 30 years, there has been a dramatic increase in the incidence of obesity worldwide, not only in adults, but also in children and adolescents ([@c49]). In parallel with the increasing obesity trends, there has been an associated doubling of the incidence of diagnosed type 2 diabetes ([@c40]), which is one of the many complications linked to obesity ([@c29]). Type 2 diabetes, the most common form of the disease, is manifested when peripheral tissues fail to properly respond to insulin, leading to elevated blood glucose. In 2011, the International Diabetes Federation estimated that around 280 million people worldwide have impaired glucose tolerance or "prediabetes"([@c26]). People with prediabetes have elevated blood glucose levels (fasting or glucose-challenged) that are not high enough to be considered diabetes, but that put these patients at a high risk of progressing to overt diabetes ([@c58]). It is estimated that by 2040, around 642 million people globally will suffer from diabetes ([@c52]). Traditional factors contributing to metabolic disruption are positive energy balance ([@c22]) and genetic predisposition ([@c25]). However, the continuous increase in the worldwide rates of obesity in infants, children, and adolescents is not easily explained by the usually cited suite of accepted risk factors ([@c10]; [@c51]) and suggests that the environment during early development may play a critical role in disease later in life ([@c23]).

Type 2 diabetes has been associated with exposure to endocrine-disrupting chemicals (EDCs) that may alter glucose homeostasis by affecting different mechanisms, such as oxidative stress or promoting adipose tissue dysfunction ([@c24]). *In vitro* studies on human and mouse islets of Langerhans showed that environmentally relevant doses of bisphenol A (BPA) alter $\beta\text{-cell}$ function via activation of estrogen receptor-beta ([@c56]). Acute exposure to high doses of the organotin triphenyltin (TPT) disrupted $\beta\text{-cell}$ function in rodents, which was reflected as a decrease in insulin secretion although no apparent morphological alteration of the pancreatic $\beta\text{-cells}$ was detected ([@c45]). Alternatively, EDCs may also disturb insulin signaling of downstream pathways in target tissues such as muscle, liver, or adipose tissue ([@c24]; [@c44]).

EDCs have also been causally linked to the development of obesity ([@c24]; [@c35]; [@c48]). Our laboratory coined the term obesogen to describe chemicals that induce abnormal fat storage *in vivo* and, therefore, may alter lipid homeostasis in the human body, leading to obesity ([@c20]) An increasing list of potential obesogens, including plasticizers, pesticides, and herbicides, has been described already using both *in vitro* and *in vivo* models (reviewed in [@c24]). One of the better-characterized obesogens is tributyltin (TBT), which activates the peroxisome proliferator--activated receptor gamma ($\text{PPAR}\gamma$) and its heterodimeric partner, the retinoid X receptor alpha ($\text{RXR}\alpha$) ([@c21]; [@c30]). Although $\text{PPAR}\gamma$ is considered the "master" regulator of adipogenesis ([@c59]), we recently showed that signaling through $\text{RXR}\alpha$, and the $\text{RXR}\alpha$ half of the $\text{RXR}\alpha\text{-PPAR}\gamma$ heterodimer was required to commit mesenchymal stem cells (MSCs) to the adipocyte linage ([@c55]). *In vivo* exposure to TBT during *in utero* development in mice led to increased fat accumulation, nonalcoholic fatty liver, and a shift in the MSC compartment to favor differentiation into adipocytes at the expense of bone ([@c8]; [@c21]; [@c36]). Strikingly, these effects of F0 exposure were transgenerationally transmitted to at least four subsequent generations in mice ([@c8]; [@c9]). Integrative methylome, transcriptome, and chromatin accessibility analyses in both somatic tissue and germline of animals ancestrally exposed to TBT suggest that TBT may exert its transgenerational effects by eliciting changes in nuclear architecture. These changes then lead to alterations in epigenetic marks and in the transcription levels of metabolic genes that contribute to the obese phenotype ([@c9]). Taken together, these data implicate TBT and potentially its metabolites as overlooked contributors to the obesity epidemic.

The major degradation product of TBT *in vivo* is dibutyltin (DBT), which is also used industrially in the manufacture of polyvinyl chloride (PVC) plastics ([@c18]), used in construction materials (e.g., door and window frames, vinyl flooring, vinyl blinds, and water pipes to name a few), medical devices (e.g., tubing and packaging), and seat coverings in automobiles. DBT leaches from PVC pipes or medical tubing into the liquid they contain or transport ([@c54]). DBT is also found in house dust ([@c19]; [@c34]) and in seafood ([@c31]; [@c32]; [@c39]), which suggests that human exposure may be widespread. The few human biomonitoring studies available show that the average concentration of DBT in blood is $\sim 4\,\text{ng}/\text{ml}$, or $\sim 16\,\text{nM}$ ([@c33]). The Agency for Toxic Substances & Disease Registry (ATSDR) determined the lowest-observed adverse-effect level (LOAEL) for intermediate-duration exposure (15--364 d) of DBT in rodents as $5\;{mg}/{kg}/\text{day}$ ([@c3]). After applying an uncertainty factor of 1,000 (10 for animal-to-human extrapolation, 10 for the use of LOAEL instead of the No-observed Adverse Effect Level (NOAEL), and 10 for human variability), the tolerable daily intake for humans was set at $0.005\;{mg}/{kg}/\text{day}$ ([@c3]).

*In vivo* studies have shown that adult exposure to relatively high doses ($6\;{mg}/{kg}$) of DBT led to acute pancreatitis and pancreatic fibrosis in rodents ([@c41]; [@c42]; [@c63]). Exposure of pregnant rats and nonhuman primates to DBT decreased fetal implantation ([@c14]; [@c15]) and increased fetal malformations and teratogenesis ([@c12], [@c13]; [@c50]). Despite the consistency of the data showing the detrimental effect of DBT during *in utero* exposure in different animal models, the mechanism underlying these phenotypes remains largely unknown.

We first reported that DBT activated human $\text{RXR}\alpha$ at micromolar concentrations ([@c21]). More recently, transfection assays performed in HeLa cells showed that DBT activated $\text{PPAR}\gamma$ ([@c43]); however, the species from whom the gene was cloned was not specified. Studies performed using the murine preadipocyte cell line 3T3-L1 and the MSC-like mouse cell line BMS2 showed that DBT induced lipid accumulation when the cells were induced to differentiate into adipocytes ([@c43]; [@c60]). Here we evaluated the ability of DBT to activate human and mouse $\text{PPAR}\gamma$ and its heterodimeric partners, human and mouse $\text{RXR}\alpha$, respectively. We investigated the adipogenic effects of DBT in human and mouse MSCs and evaluated the expression of adipogenic markers, such as fatty acid binding protein-4 (FABP4), lipoprotein lipase (LPL), and fat-specific protein-27 (FSP27) in both species. We also tested the obesogenic effects of DBT *in vivo* by exposing pregnant C57BL/6J mice throughout pregnancy and lactation at dosages well below the LOAEL and measuring fat accumulation, glucose tolerance, and plasma leptin, all of which are risk factors for diabetes.

Methods {#s2}
=======

Chemicals and Reagents {#s2.1}
----------------------

TBT, DBT, dexamethasone, isobutylmethylxanthine, Nile Red, Oil Red O, Hoechst 33342, glucose, human recombinant insulin, and carboxymethylcellulose (CMC) were purchased from Sigma-Aldrich. Rosiglitazone (ROSI) was purchased from Cayman Chemicals, and T0070907 from Enzo Life Sciences. IRX194204 was a gift from Dr. Rosh Chandraratma (IO Therapeutics). Dimethylsulfoxide (DMSO) was purchased from Thermo Fisher Scientific, Inc. Calf bovine serum (CBS) was purchased from Atlanta Biologicals, and fetal bovine serum (FBS) was purchased from Gemini Bio-Products.

Transient Transfection Assays {#s2.2}
-----------------------------

pCMX-GAL4 ([@c17]) and fusion constructs to nuclear receptor ligand-binding domains for mouse and human $\text{PPAR}\gamma$ were described previously ([@c16]; [@c64]). Full-length $\text{pSG}5\text{-mRXR}\alpha$ (a gift from Dr. Roland Schuele, University of Freiburg, Germany) and $\text{pCMX}\text{-hRXR}\alpha$ ([@c61]) constructs were used to test RXR activation using the reporter tk-(ApoA1)x4-luc ([@c5]). Transient transfections were performed in COS7 cells (ATCC^®^ CRL-1,651™) as described ([@c28]). Briefly, COS7 cells were seeded at 15,000 cells per well in 96-well tissue culture plates with Dulbecco's Modified Eagle Medium (DMEM; HyClone), supplemented with 10% CBS. Cells were transfected when they reached $\sim 90\%$ confluency ($\sim 24h$ after seeding). One microgram of effector plasmid was co-transfected with $5\;\mu g$ of reporter and $5\;\mu g$ of $\text{pCMX-}\beta\text{-galactosidase}$ ([@c17]) transfection control plasmids per 96-well plate in Opti-MEM® using Lipofectamine® 2000 reagent (Invitrogen™; Life Technologies), following the manufacturer's recommended protocol. After overnight incubation, the medium was replaced with DMEM supplemented with 10% resin charcoal stripped FBS plus ligands or vehicle control for an additional 24 h. DBT was tested from $10^{–10}M$ to $10^{–5}M$, with $10^{–5}M$ producing noticeable cytotoxicity as judged by reduced $\beta\text{-galactosidase}$ activity (Table S1). The control compounds ROSI ($\text{PPAR}\gamma$ agonist), IRX4204 (4204; RXR agonist), and TBT ($\text{PPAR}\gamma$ and RXR agonist) were tested from $10^{–10}M$ to $10^{–5}M$. In addition, 24 h after adding the ligands to the media, cells were lysed in $165\;\mu l$ of lysis buffer \[$25\,\text{mM}$ Tris-phosphate (pH 7.8), 15% glycerol, 2% 3-((3-cholamidopropyl) dimethylammonio)-1-propanesulfonate (CHAPS), 1% lecithin, 1% bovine serum albumin (BSA), $4\,\text{mM}$ ethylene $\text{glycol-bis}\left( \beta\text{-aminoethyl\ ether} \right)\text{-}N,N,N\prime,N\prime\text{-tetraacetic}$ acid (EGTA), $6\,\text{mM}$ Magnesium Chloride ($\text{MgCl}_{2}$), $1\,\text{mM}$ dithiothreitol (DTT), $1\,\text{mM}$ and 4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride (AEBSF)\] and allowed to shake for 30 min at room temperature (RT) 22°C. For luciferase assay, $50\;\mu l$ of the lysate from each well was transferred to a well in a clean, nontreated, white, flat-bottom, polystyrene, 96-well plate (Costar). Additionally, $100\;\mu l$ of luciferase solution \[$4.28\,\text{mM}$ magnesium carbonate hydroxide pentahydrate $({\left( \text{MgCO}_{3} \right)_{4}{Mg}\left( \text{OH} \right)_{2}5H_{2}O})$, $10.68\,\text{mM}$ magnesium sulfate ($\text{MgSO}_{4}$), $80\,\text{mM}$ Tricine (pH 7.8), $0.4\,\text{mM}$ ethylendinitrilo tetraacetic acid (EDTA) (pH 8.0), $5\,\text{mM}$ DTT, $0.15\;{mg}/{mL}$ Coenzyme A, $0.5\,\text{mM}$ adenosine triphosphate (ATP), and $0.5\,\text{mM}$ Luciferin\] made fresh was added to each well with the cell lysate, and that plate was shaken for 30 s at RT. Plates were placed in Dynatech ML3000 luminometer, and data were acquired with luminometer ML3000 (version 3.07) software. For $\beta\text{-galactosidase}$ assay, $50\;\mu l$ of the cell lysate was transferred to a clear, flat-bottom, 96-well plate (Thermo Fisher Scientific). In addition, $100\;\mu l$ of $\beta\text{-galactosidase}$ solution \[$60\,\text{mM}$ sodium phosphate dibasic (${Na}_{2}\text{HPO}_{4}$), $40\,\text{mM}$ sodium phosphate monobasic ($\text{NaH}_{2}\text{PO}_{4}$), $10\,\text{mM}$ potassium chloride (KCl), and $1\,\text{mM}$ magnesium chloride ($\text{MgCl}_{2}$), 0.3% $\beta\text{-Mercaptoethanol}$, and $0.5–3\;{mg}/{mL}$ o-nitrophenyl $\beta\text{-}D\text{-galactopyranoside}$ (ONPG)\] was added to each well. Plates were shaken for 30 s and incubated at RT for 15 min. Absorbance was measured with a wavelength of $405\,\text{nm}$ on a Versamax microplate reader (Molecular Devices) and SOFTmaxPRO 4.0 software. Each luciferase read was normalized with the corresponding $\beta\text{-galactosidase}$ read coming from the same transfection well and multiplied by the number of minutes the $\beta\text{-galactosidase}$ plate was incubated (15 min). All transfections were performed in triplicate and reproduced in at least 4 independent experiments. Data are reported as relative light units (luciferase/$\beta\text{-galactosidase}$) or as fold induction over vehicle (0.05% DMSO) $\text{controls} \pm \text{standard}\,\text{error}\,\text{of}\,\text{the}\,\text{mean}\,\left( \text{SEM} \right)$ calculated using standard propagation of error ([@c4]).

$\text{EC}_{50}$ and maximum activations were calculated using GraphPad Prism 7.0 (GraphPad Software, Inc.) as follows: Concentrations were transformed to logarithmic scale, and a nonlinear regression was calculated using the "log(agonist) vs. normalized response -- Variable slope" function. Significance between $\text{EC}_{50}$ for human and mouse isoforms in the presence of DBT were calculated by testing differences of best-fit values between datasets.

Adipogenic Differentiation {#s2.3}
--------------------------

Mouse bone-marrow MSCs (mMSCs) were purchased from Oricell (Cyagen Biosciences), and human bone-marrow MSCs (hMSCs) were obtained from the Texas A&M Health Science Center Institute for Regenerative Medicine. Human and mouse MSCs were maintained and differentiated as described using the same media and differentiation procedure for both species ([@c55]). Briefly, 80,000 cells per well were seeded in a 12-well plate and maintained in DMEM supplemented with 10% CBS. When cells reached 80--90% confluency, media were replaced with differentiation media \[Alpha Modification of Eagle's Medium ($\alpha\text{MEM}$), 15% FBS supplemented with adipogenic induction cocktail (MDI: $500\,\text{micromolar}$ isobutylmethylxanthine, $1\,\text{micromolar}$ dexamethasone, $5\;{microgram}/{mL}$ human recombinant insulin and ligands\]. Specific ligands \[$500\,\text{nM}$ ROSI, $50\,\text{nM}$ TBT or DBT ($1–100\,\text{nM}$) dissolved in DMSO\] were administered every 3 d for 14 d. Antagonist assays were performed similarly, except that $100\,\text{nM}$ T0070907 or vehicle control were added every 8 h due to the instability of the antagonist. DMSO concentrations in the medium were identical between vehicle controls and test chemicals and never exceeded 0.1%. At the end of each assay, cells were either fixed in 3.7% formaldehyde in PBS for 30 min at RT for lipid staining or homogenized in TriPure (Roche) for gene-expression analysis.

Measurement of Lipid Accumulation and mRNA Quantitation {#s2.4}
-------------------------------------------------------

Analyses of lipid accumulation with Nile Red and Oil Red O were performed as previously described ([@c7]; [@c28]). Briefly, neutral lipids and nucleic acids were stained with Nile Red ($1\;{mg}/{mL}$) and Hoechst 33342 ($1\;{mg}/{mL}$), respectively. Total fluorescence per well was measured in a SpectraMax Gemini XS spectrofluorometer (Molecular Devices) using SoftMax Pro (Molecular Devices); Nile Red relative fluorescence units (RFU) were normalized to Hoechst RFU for each well to account for cell density. For Oil Red O staining, the same cells that were stained with Nile Red were washed with 60% isopropyl alcohol twice. Oil Red O staining solution was freshly made \[3 parts of Oil Red O stock solution (0.3% (w/v) Oil Red O/isopropyl alcohol) and 2 parts of distilled water\] and filtered twice to remove any precipitates. Cells were stained for 30 min following three washes with 60% isopropyl alcohol and subsequently maintained at 4°C in PBS until analyses. Cells were imaged using a Zeiss Axiovert 40 CFL microscope (Zeiss).

For reverse transcription and quantitative real time PCR (RT-QPCR), total RNA in TriPure (Roche) was isolated as recommended by the manufacturer. Complementary DNA was generated from $1\;\mu g$ of DNAse-treated total RNA using transcriptor reverse transcription (Roche), according to the manufacturer's protocol. RT-QPCR was performed using Sybr Green Master Mix (Roche), and cDNA was quantitated in a Light Cycler 480 System (Roche) using primer sets listed in Table S2. Each primer set amplified a single band as determined by gel electrophoresis and melting curve analysis (Figure S1). RT-QPCR data were analyzed by the $2^{- \Delta\Delta\text{Ct}}$ method ([@c38]) relative to ribosomal protein 36B4 (a.k.a., RPLP0), normalizing to 0.1% DMSO vehicle. Error bars represent the SEM from four to six biological replicates, calculated using standard propagation of error ([@c4]).

Animal Maintenance and Exposure {#s2.5}
-------------------------------

Male and female C57BL/6J mice (7 weeks of age) were purchased from the Jackson Laboratory and housed in micro-isolator cages in a temperature-controlled room (25--28°C) with a 12-h light/dark cycle. Water and food were provided *ad libitum* unless otherwise indicated. Animals were treated humanely and with regard for alleviation of suffering. All procedures conducted in this study were approved by the Institutional Animal Care and Use Committee of the University of California, Irvine. All tissue harvesting was performed with the dissector blinded to which group the animal belonged to. At the moment of euthanasia, each mouse was assigned a code, known only to a lab member not involved in the dissection process.

We first performed a pilot experiment (set 1) in which animals were exposed to the chemicals during *in utero* development and lactation. Animals from set 1 were maintained on a standard diet (SD - Rodent Diet 20 5053\*; PicoLab; 13.4% KCal from fat) throughout the experiment until euthanasia on week 8. Animals from set 2 were exposed similarly to animals from set 1 but were fed with a diet with higher fat content (HFD - Mouse Diet 20 5058\*; PicoLab; 21.2% KCal from fat) from week 4 until euthanasia at week 17.

Animal numbers required for the dietary challenge were estimated using *a priori* power analyses \[G\*Power v3.1.5\]. Based on previous data published in our laboratory ([@c9]), differences in fat content between TBT-exposed and control males when maintained with the higher fat diet (HFD) are $\geq 23\%$ with SEM within groups of $\leq 10\%$. Hence, setting type I and type II errors ($\alpha$ and $\beta$) at 0.05 and the effect size $d = 1.47$, the minimum sample size required for a power ($1–\beta$) of 0.8 was calculated to be $\geq 7$ animals per group.

Female C57BL/6J mice (8 and 12 females per treatment group for sets 1 and 2, respectively) were randomly assigned to the different treatment groups and exposed via drinking water to different concentrations of DBT (5, 50, or $500\,\text{nM}$), $50\,\text{nM}$ TBT or 0.1% DMSO vehicle (all diluted in 0.5% carboxymethyl cellulose in water to maximize solubility) for 7 d prior to mating. This TBT concentration was chosen based on our previous study ([@c8]) and is 5 times lower than the established NOAEL ([@c27]). For DBT, we referred to the established LOAEL for intermediate exposure established by the ATSDR at $5\;{mg}/{kg}/\text{day}$ for rodents ([@c3]) and chose the highest concentration in our experiment to be 100-fold lower. Therefore, we treated the water with $500\,\text{nM}$, $50\,\text{nM}$ and $5\,\text{nM}$, which is equivalent to 50, 5, and $0.5\;\mu g/{kg}/\text{day}$ (100-, 1,000-, and 10,000-fold lower than the LOAEL) assuming an average body weight of $30\; g$ and $8.5\,\text{ml}$ of water consumption per day for a pregnant C57BL/6J female. The intermediate concentration ($5\;\mu g/{kg}/\text{day}$) is equivalent to the human tolerable daily intake. Chemicals were administered to the dams throughout pregnancy and lactation. Sires were never exposed to the treatment.

Chemical exposure experiments in multiparous animals can be confounded by litter effects. Standard approaches to control for such effects in gestational exposure experiments rely primarily on using litter as the experimental \'*n*\', or selecting one male and one female per litter as representative. However, litter size and sex ratio can affect growth trajectories and subsequent body composition, which can cause litter effects when assessing metabolic endpoints such as obesity ([@c57]). To avoid this potential confounder, we strictly controlled litter sizes, rejecting litters with fewer than six or more than eight animals and litters with fewer than two members of one sex. We also tested litter size and sex distribution at each chemical dose to identify whether litter effects may have occurred. We considered both male and female offspring separately in our analysis.

Body weight and body composition were measured weekly using EchoMRI^™^ Whole Body Composition Analyzer, which provides lean, fat, and water-content information. Total water weight includes free water mainly from the bladder and water contained in lean tissue.

Glucose and insulin tolerance tests were performed at weeks 6--7 and 14--15, for sets 1 and 2, respectively. Animals were given $2\; g$ of glucose/kg body weight (bw), or $0.75\,\text{IU}$ of insulin/kg bw by intraperitoneal injection after 4 h of fasting (from 8 a.m.--12 p.m.). Glucose levels were measured with Contour^®^ blood glucose meter (Bayer) and Contour^®^ blood glucose strips (Bayer) every 30 min for 120 min after injection.

Animals were euthanized by isofluorane exposure followed by exsanguination after 16 h fasting (overnight) at weeks 8 (set 1) and 17 (set 2). Blood was drawn from direct heart puncture into a heparinized syringe and placed in a clean tube containing protease inhibitors (Protease Inhibitor Cocktail III -- Thermo Fisher Scientific). Blood was centrifuged for 10 min at $5,000\,\text{rpm}$ at 4°C. Plasma was transferred to a clean tube, snap-frozen in liquid nitrogen, and preserved at $- 80{^\circ}C$. Leptin and insulin levels from males and females were analyzed using the Mouse Leptin and Mouse Insulin ELISA kits (Cayman Chem). Adiponectin was analyzed following the manufacturer's protocol (Thermo Fisher Scientific). Based on previous studies from our laboratory ([@c9]), hormone level changes range from 25% to 220%, depending on the hormone analyzed with SEM within groups of $\leq 15\%$. Setting the conditions as described above with an effect size $d = 3.47$, the minimum sample size was calculated to be three animals per group. Pancreases were isolated, fixed in 3.7% formaldehyde in PBS, embedded in paraffin, sectioned ($5\;\mu m$), and stained with Masson's Trichrome at the University of California, Irvine Pathology Core.

Statistical Analyses {#s2.6}
--------------------

Statistical analysis and graphing for all figures was conducted in GraphPad Prism 7.0 (GraphPad Software, Inc.). For adipogenesis assay, one-way analysis of variance (ANOVA) followed by Dunnett's post-hoc test were conducted to compare DMSO and the different concentrations of DBT. Unpaired *t*-test was conducted to compare the positive controls ROSI and TBT with DMSO. Student's *t*-test was performed to compare every treatment in the presence or absence of T0070907 in the antagonist assay. For longitudinal statistical analyses of body weight and body composition, and glucose and insulin tolerance tests, two-way ANOVA followed by Sidak's post-hoc test was performed to compare the different treatments. For endocrine analyses, unpaired *t*-test was conducted to compare results between treatment samples and control. $P \leq 0.05$ was considered statistically significant.

Results {#s3}
=======

DBT and Activation of Human and Mouse $\textit{\textbf{PPAR}}\gamma$ and RXR in Vitro {#s3.1}
-------------------------------------------------------------------------------------

DBT activated human and mouse $\text{PPAR}\gamma$ and $\text{RXR}\alpha$ at micromolar concentrations ([Figure 1](#f1){ref-type="fig"}). DBT was approximately equipotent on human and mouse $\text{PPAR}\gamma$ ($p < 0.05$), but it was a more efficacious activator of the mouse receptor ([Figure 1](#f1){ref-type="fig"}; Figure S2; Table S3). In contrast, DBT was a somewhat more potent ($p < 0.0001$) and efficacious activator of human $\text{RXR}\alpha$ than of mouse $\text{RXR}\alpha$ ([Figure 1](#f1){ref-type="fig"}, Figure S2; Table S3).

![Activation of human and mouse isoforms of $\text{PPAR}\gamma$ and RXR by DBT. (A, B) Mouse and human $\text{PPAR}\gamma$ and (C, D) $\text{RXR}\alpha$ activation by increasing doses of DBT was tested in transiently transfected COS7 cells. ROSI and TBT were used as positive controls for $\text{PPAR}\gamma$ activation and TBT and 4204 were positive controls for $\text{RXR}\alpha$ activation. DBT and TBT were tested in 3-fold serial dilutions, while ROSI and 4204 were tested in 10-fold serial dilutions. Luciferase values were normalized with $\beta\text{-galactosidase}$ transfection controls. Each data point represents the average of triplicates for each chemical and $\text{concentration} \pm \text{SEM}.$ Note: 4204, IRX194204; DBT, dibutyltin; DMSO, dimethylsulfoxide; M, molar; h/mPPARg, human/mouse peroxisome proliferator--activated receptor gamma; h/mRXR, human/mouse retinoid X receptor; ROSI, rosiglitazone; SEM, standard error of the mean; TBT, tributyltin.](EHP3030_f1){#f1}

DBT and Molecular Mechanisms of Lipid Accumulation in Human and Mouse MSCs {#s3.2}
--------------------------------------------------------------------------

In both hMSCs and mMSCs, $100\,\text{nM}$ DBT (but not lower concentrations) significantly increased lipid accumulation after 14 d of exposure ([Figure 2A, C](#f2){ref-type="fig"} and Figure S3). In addition, hMSCs were more responsive to DBT than mMSCs in lipid accumulation ([Fig. 2A](#f2){ref-type="fig"} and [2C](#f2){ref-type="fig"}). Therefore, $100\,\text{nM}$ DBT was used in subsequent experiments. RT-QPCR analyses of steady state mRNA levels showed higher levels of $C/\text{EBP}\alpha$ and $\text{PPAR}\gamma 2$, which regulated each other in a positive feedback loop early in adipose differentiation ([@c11]), in the DBT-treated MSCs than in the DMSO controls ([Figure 2B, D](#f2){ref-type="fig"}). The levels of mRNAs encoding other adipogenic markers such as fatty acid binding protein-4 (FABP4), fat-specific protein-27 (FSP27), and lipoprotein lipase (LPL) were also higher in DBT-exposed cells ([Figure 2B, D](#f2){ref-type="fig"}).

![DBT and adipogenesis in human and mouse MSCs. Adipogenic differentiation was induced in (A, B) human and (C, D) mouse MSCs in the presence of adipogenic cocktail (MDI) and DBT ($1\,\text{nM}–100\,\text{nM}$); $500\,\text{nM}$ ROSI and $50\,\text{nM}$ TBT were used as positive controls and data were compared to 0.1% DMSO (vehicle). Media were replaced with fresh cocktail and ligands every 3 d for 14 d. (A, C) Graphs show lipid accumulation represented as the ratio between relative fluorescence units (RFU) of Nile Red and Hoechst. Hoechst is used to normalize lipid content to the number of cells per well. Each bar represents the average of 6 $\text{replicates} \pm \text{SEM}.$ (B, D). Gene expression is reported as fold induction over vehicle (0.1% DMSO) $\text{controls} \pm \text{SEM}.$ One-way analysis of variance (ANOVA) was conducted to compare DMSO and the different concentrations of DBT, followed by Dunnett's post-hoc test. Unpaired *t*-test was conducted for the positive controls ROSI and TBT versus vehicle. Note: $C/\text{EBP}\alpha$, CCAAT/Enhancer Binding Protein Alpha; DBT, dibutyltin; DMSO, dimethylsulfoxide; Fabp4, fatty acid binding protein-4; Fsp27, fat-specific protein-27; LPL: lipoprotein lipase; h/mMSCs, human/mouse mesenchymal stem cells; $\text{PPAR}\gamma 2$, peroxisome proliferator--activated receptor gamma; ROSI, rosiglitazone; SEM, standard error of the mean; TBT, tributyltin. \*$p \leq 0.05$ in comparison with vehicle.](EHP3030_f2){#f2}

To determine whether the induction of lipid accumulation after DBT exposure was due to the activation of the $\text{PPAR}\gamma$ pathway, we tested the effect of DBT exposure in the presence and absence of the specific $\text{PPAR}\gamma$ antagonist T0070907. Cells exposed to $500\,\text{nM}$ ROSI or $50\,\text{nM}$ TBT served as positive controls for the assay because they both activate $\text{PPAR}\gamma$ at these doses. In hMSCs, T0070907 ($100\,\text{nM}$) significantly blocked the ability of DBT to induce the accumulation of lipids ([Figure 3A](#f3){ref-type="fig"} and Figure S4A). This effect was less evident in mMSCs than in hMSCs ([Figure 3C](#f3){ref-type="fig"} and Figure S4B). Gene expression analysis of $C/\text{EBP}\alpha$, $\text{PPAR}\gamma 2$, FABP4, LPL, and FSP27 after T0070907 treatment revealed a statistically significant decrease in steady state mRNA levels of these genes except for $C/\text{EBP}\alpha$ and $\text{PPAR}\gamma 2$ in mMSCs ([Figure 3B--D](#f3){ref-type="fig"}).

![$\text{PPAR}\gamma$ antagonist T0070907 effects on DBT-induced adipogenesis in human and mouse MSCs. Adipogenesis was induced in (A, B) human and (C, D) mouse MSCs with adipogenic cocktail (MDI) and $100\,\text{nM}$ DBT in the presence or absence of the $\text{PPAR}\gamma$ antagonist T0070907 ($100\,\text{nM}$). (A, C) Lipid accumulation is presented as the ratio of relative fluorescence units (RFUs) of Nile Red and Hoechst. (B, D) Gene expression levels of adipogenic markers expressed as fold induction over vehicle. Media with adipogenic cocktail and ligands was replaced every 3 d for 14 d. Fresh T0070907 was added every 8 h throughout the experiment. One-way analysis of variance (ANOVA) was conducted to compare DMSO and the different concentrations of DBT, followed by Dunnett's post-hoc test. Unpaired *t*-test was conducted for the positive controls ROSI and TBT versus vehicle. Student's *t*-test was performed to compare every treatment in the presence or absence of T0070907. All data are expressed as the average of 6 $\text{replicates} \pm \text{SEM}.$ Note: $C/\text{EBP}\alpha$, CCAAT/Enhancer Binding Protein Alpha; DBT, dibutyltin; DMSO,dimethylsulfoxide; Fabp4,fatty acid binding protein-4; Fsp27, fat-specific protein-27; LPL, lipoprotein lipase; h/mMSCs, human/mouse mesenchymal stem cells; $\text{PPAR}\gamma 2$, peroxisome proliferator--activated receptor gamma; ROSI, rosiglitazone; SEM, standard error of the mean; TBT, tributyltin. \*$p \leq 0.05$ in comparison with vehicle (DMSO). \#$p \leq 0.05$ comparing T0070907 samples with DMSO samples within the same treatment.](EHP3030_f3){#f3}

Body Composition Analysis in Mice Perinatally Exposed to DBT or TBT {#s3.3}
-------------------------------------------------------------------

We consistently found a reduction in the pup survival in litters coming from dams exposed to $5\,\text{nM}$ DBT (Table S4). Therefore, to avoid any artefactual litter effects, we removed the $5\,\text{nM}$ treatment group from the analyses. We did not observe statistically significant differences in body weight or body composition in animals from set 1 (on standard diet) throughout the experiment ([Figure 4A--B](#f4){ref-type="fig"}). However, we found that males from set 2 (high-fat diet) perinatally exposed to $500\,\text{nM}$ DBT accumulated a significantly larger amount of fat than did controls ([Figure 4C](#f4){ref-type="fig"}). The difference became apparent at 8 wk but did not reach statistical significance until 11 wk. Animals exposed to $50\,\text{nM}$ TBT also tended to accumulate more fat than controls when exposed to the HFD, although the difference did not reach statistical significance ([Figure 4C](#f4){ref-type="fig"}). Females did not show any significant difference in body weight or fat content ([Figure 4D](#f4){ref-type="fig"}).

![Body weight and fat storage in animals perinatally exposed to DBT from sets 1 and 2. Body weight and fat content in males (A, C) and females (B, D) from sets 1 (A, B) and 2 (C, D). Animals from set 1were maintained on a standard diet (SD) throughout the experiment. Animals from set 2 were maintained on SD until week 4 when their diet was switched to one with a slight increase in fat content (HFD: High fat diet). Fat content was normalized to body weight for each animal individually. Two-way analysis of variance (ANOVA) was conducted to compare DMSO and the different treatments, followed by Sidak's post-hoc test to compare treatments within each time point. $N\,\geqq\, 6$ Data are expressed as the $\text{mean} \pm \text{SEM}$. Note: DBT, dibutyltin; DMSO, dimethylsulfoxide; TBT, tributyltin. \*$p \leq 0.05$ for animals treated with $500\,\text{nM}$ DBT compared to those treated with vehicle (DMSO).](EHP3030_f4){#f4}

Glucose and Insulin Sensitivity in Mice Perinatally Exposed to DBT {#s3.4}
------------------------------------------------------------------

Results of glucose and insulin tolerance tests (GTT and ITT, respectively) performed in both sets (weeks 6--7 and weeks 14--15 for sets 1 and 2, respectively) indicated no alterations in glucose or insulin tolerance in animals from set 1 ([Figure 5](#f5){ref-type="fig"}). However, males exposed to $500\,\text{nM}$ DBT and to the HFD (set 2) did not metabolize glucose as rapidly as control animals during the GTT ([Figure 6A--B](#f6){ref-type="fig"}). There were no differences in glucose metabolism during the insulin tolerance test ([Figure 6C--D](#f6){ref-type="fig"}). We did not find significant differences in glucose or insulin tolerance among females in any of the treatments ([Figure 7](#f7){ref-type="fig"}). Fasting glucose levels were increased in the male and female animals from set 2 who were treated with $500\,\text{nM}$ DBT, but only in female animals who were treated with $50\,\text{nM}$ TBT ([Figure 6E](#f6){ref-type="fig"} and [Figure 7E](#f7){ref-type="fig"}). To test whether this effect was due to a decrease in insulin levels, we measured insulin as well as adiponectin and leptin levels in plasma from both males and females exposed to $500\,\text{nM}$ DBT, $50\,\text{nM}$ TBT, and controls. Leptin levels were significantly higher in males, but not in females, from both TBT and $500\,\text{nM}$ DBT groups ([Figure 6F](#f6){ref-type="fig"} and [Figure 7F](#f7){ref-type="fig"}) than in DMSO controls. We did not find significant differences in insulin or adiponectin levels among groups ([Figure 6F--H](#f6){ref-type="fig"} and [Figure 7F--H](#f7){ref-type="fig"}). We did not find any litter bias in these results.

![DBT effects on glucose homeostasis in males and females from set 1. Glucose levels and area under the curve (AUC) during glucose tolerance (A, B) and insulin tolerance (C, D) tests in males and females. Animals were fasted for 4 h prior to the test. Glucose or insulin was administered by intraperitoneal injection and glucose levels were measured every 30 min for the next 120 min. AUC was calculated for each animal independently and averaged for each treatment group. Two-way analysis of variance (ANOVA) was conducted to compare DMSO and the different treatments, followed by Sidak's post-hoc test for glucose levels at each time point. One-way ANOVA was conducted to compare DMSO and the different concentrations of DBT, followed by Dunnett's post-hoc test to compare differences in AUC. Unpaired *t*-test was conducted for TBT versus vehicle. $N\,\geqq\, 6$. Data are expressed as the $\text{mean} \pm \text{SEM}.$ Note: DBT, dibutyltin; DMSO, dimethylsulfoxide; SEM,standard error of the mean; TBT, tributyltin.](EHP3030_f5){#f5}

![DBT effects on glucose homeostasis, fasting glucose, and leptin levels in males exposed to HFD. (A) Glucose levels during glucose tolerance test (GTT). (B) Area under the curve (AUC) corresponding to the GTT. (C) Glucose levels during insulin tolerance test (ITT). (D) Area under the curve (AUC) corresponding to the ITT. Animals perinatally exposed to DMSO, TBT or DBT were fasted for 4 h prior to the test. Glucose or insulin as administered by intraperitoneal injection and glucose levels were measured every 30 min for the next 120 min. AUC was calculated for each animal independently and averaged for each treatment group. (E) Glucose, (F) leptin, (G) insulin and (H) adiponectin levels after 16 h fasting. Blood was isolated by heart puncture after euthanasia and process for plasma analyses. Two-way analysis of variance (ANOVA) was conducted to compare DMSO and the different treatments, followed by Sidak's post-hoc test for glucose levels at each time point for GTT and ITT. One-way ANOVA was conducted to compare DMSO and the different concentrations of DBT, followed by Dunnett's post-hoc test to compare differences in AUC and glucose levels. Unpaired *t*-test was conducted for DMSO vs. TBT and DMSO vs. $500\,\text{nM}$ DBT comparisons of hormones. $N\,\geqq\, 9$. Data are expressed as the $\text{mean} \pm \text{SEM}.$ Note: DBT, dibutyltin; DMSO, dimethylsulfoxide; TBT, tributyltin; SEM, standard error of the mean. \*$p \leq 0.05$ in comparison with vehicle (DMSO).](EHP3030_f6){#f6}

![DBT effects on glucose homeostasis, fasting glucose, and leptin levels in females exposed to HFD. (A) Glucose levels during glucose tolerance test (GTT). (B) Area under the curve (AUC) corresponding to the GTT. (C) Glucose levels during insulin tolerance test (ITT). (D) Area under the curve (AUC) corresponding to the ITT. Animals were fasted for 4 h prior to the test. Glucose or insulin were injected by intraperitoneal injection and glucose levels were measured every 30 min for the next 120 min. AUC was calculated for each animal independently and averaged for each treatment group. (E) Glucose, (F) insulin, (G) leptin and (H) adiponectin levels after 16 h fasting. Two-way analysis of variance (ANOVA) was conducted to compare DMSO and the different treatments, followed by Sidak´s post-hoc test for glucose level at each time point. One-way ANOVA was conducted to compare DMSO and the different concentrations of DBT, followed by Dunnett's post-hoc test to compare differences in AUC and glucose levels. Unpaired *t*-test was conducted for DMSO vs. TBT and DMSO vs. $500\,\text{nM}$ DBT comparisons for hormone levels. $N\geqq 9$ animals per group. Data are expressed as the $\text{mean} \pm \text{SEM}.$ Note: DBT, dibutyltin; DMSO, dimethylsulfoxide; TBT, tributyltin. \*\*\*$p \leq 0.001$ compared to vehicle (DMSO).](EHP3030_f7){#f7}

We evaluated pancreas histology in the DBT animals exposed to $500\,\text{nM}$ DBT from set 2 to further characterize the glucose intolerant phenotype observed. No discernible alterations in pancreas morphology, including the numbers and sizes of islets of Langerhans were observed ([Figure 8](#f8){ref-type="fig"}).

![Analysis of pancreas morphology in males maintained on a high fat diet. Representative sections of pancreases stained with Masson's Trichrome for animals perinatally exposed to (A) DMSO, (B) TBT and (C) $500\,\text{nM}$ DBT. (D) Average number of islets of Langerhans normalized by the area of the section. (E) Area of islets of Langerhans for each treatment in arbitrary units. Unpaired t-test was conducted for DMSO vs. TBT and DMSO vs. $500\,\text{nM}$ DBT statistical analyses. $N\,\geqq\, 9$. Data are expressed as the $\text{mean} \pm \text{SEM}.$ Scale bar: $200\;\mu m$. Note: DBT, dibutyltin; DMSO, dimethylsulfoxide; SEM, standard error of the mean; TBT, tributyltin.](EHP3030_f8){#f8}

Discussion {#s4}
==========

The obesogens TBT and triphenyltin have been previously shown to activate both $\text{PPAR}\gamma$ and $\text{RXR}\alpha$ and to increase lipid storage in adipocytes ([@c21]; [@c30]). A human study showed that placental levels of TBT were directly linked to increased body weight in infants during the first 3 months after birth ([@c53]), suggesting that obesogen exposure during embryogenesis might play an important role in obesity later in life in humans. *In vivo* studies in mouse models showed that *in utero* exposure to TBT increases fat storage, promotes hepatic steatosis, and biases the MSC compartment toward the adipogenic lineage ([@c8]; [@c21]; [@c36]). We found that these effects were transgenerationally transmitted through the F3 ([@c8]) and the F4 generations, and recently proposed that changes in nuclear architecture caused by TBT exposure may be driving this phenotype ([@c9]).

Here we investigated potential obesogenic effects of DBT, the major *in vivo* metabolite of TBT. DBT is also widely used at high concentrations in vinyl and other forms of PVC plastics ([@c18]; [@c54]). In this study, DBT activated mouse and human $\text{PPAR}\gamma$ and $\text{RXR}\alpha$ and increased lipid accumulation in MSCs in a $\text{PPAR}\gamma\text{-dependent}$ manner. Perinatal exposure to DBT led to increased fat storage, glucose intolerance, and increased leptin levels in male mice when animals were challenged with a diet containing slightly higher levels of fat (21.2% vs. 13.4% KCal from fat). Males exposed to TBT did not show any alteration in glucose or insulin tolerance although they had increased levels of leptin and tended to accumulate more fat than did controls when exposed to a HFD. Although to our knowledge there are no reports concerning food intake in animals exposed to DBT, it has been reported that exposure of adult male mice to TBT reduced food intake ([@c6]). However, it was also reported in the same study that those animals developed dermatitis and hair loss during the experiment. Those observations suggest that, even though the concentration of TBT used in that study was lower than the NOAEL ($0.025\;{mg}/{kg}$), it had a potential toxic effect affecting appetite. Therefore, we recommend that further analyses that evaluate food intake and activity after perinatal exposure to DBT be performed to establish whether DBT is affecting appetite. Females exposed to DBT or TBT also had increased fasting plasma glucose levels, although we did not detect any changes in glucose tolerance or in fat storage in comparison with controls. Because males and females are metabolically different, we speculate that differences in fat storage might become evident at older ages in females.

Leptin is an important regulator of energy and glucose homeostasis secreted by the white adipose tissue ([@c46]). The principal target of leptin is the arcuate nucleus of the hypothalamus, although other tissues such as liver can respond to leptin signaling ([@c1]; [@c46]). The function of leptin was initially thought to be exclusively the regulation of appetite by acting as a satiety signal following food intake ([@c46]). Leptin resistance occurs when leptin levels in obese individuals are increased, but the downstream signaling is disrupted, which includes autonomic signals to mobilize fat ([@c62]). This disruption breaks the circuit that regulates food intake, which may lead to obesity and other metabolic disorders ([@c47]). It is now known that leptin also plays an important role in glucose homeostasis ([@c37]). Koch et al. found that in leptin-deficient mice, exogenous insulin improved glucose tolerance only in the presence of exogenous leptin, and that cells located in the arcuate nucleus were responding to the exogenous injection of both molecules ([@c37]). Their results suggest that the inhibition of the leptin-signaling pathways using leptin- and leptin receptor-deficient mice significantly reduced insulin sensitivity in the brain, which led to the disruption of glucose homeostasis ([@c37]).

We found that despite having increased leptin levels, the animals perinatally exposed to $500\,\text{nM}$ DBT failed to metabolize glucose efficiently. However, when exogenous insulin was injected, the animals metabolized glucose at the same rate as controls, suggesting that the disturbance was not related to a lack of insulin sensitivity in peripheral tissues, such as liver, muscle, or fat. Moreover, histological analysis of the pancreas showed that overall morphology as well as the number and size of islets of Langerhans were normal in animals exposed *in utero* to $500\,\text{nM}$ DBT in this study. These results suggest that the impaired glucose tolerance might be driven by hypothalamic leptin resistance rather than impaired $\beta\text{-cell}$ insulin secretion. Taken together, we infer from these data that perinatal exposure to environmentally relevant doses of DBT led to a prediabetic phenotype in male mice. Allowing the animals to age or challenging them with diets containing a higher fat or carbohydrate content may result in progression to overt diabetes.

Prediabetes in humans is defined by elevated fasting glucose or impaired glucose metabolism following oral glucose challenge; along with obesity, prediabetes is a major risk factor for the development of type 2 diabetes and cardiovascular disease ([@c2]). Accepted risk factors for the development of obesity and diabetes are poor diet and lack of exercise; however, there is a growing body of evidence showing that environmental pollutants, such as obesogens and other metabolic disruptors, might be important contributors to the global diabetes epidemic ([@c24]; [@c44]). A detailed evaluation of under-studied risk factors, such as obesogen exposure, in human cohorts is required to better understand the extent to which these chemicals are driving the prevalence of type 2 diabetes.

The dose of DBT at which we observed statistically significant obesogenic and prediabetic effects in our animal model was $500\,\text{nM}$ when administered during *in utero* development and lactation via drinking water. This concentration of DBT is equivalent to a daily intake of $50\;\mu g/{kg}/\text{day}$ (assuming an average body weight of $30\; g$ and $8.5\,\text{ml}$ of water consumption per day for a pregnant C57BL/6J female), which is 100-fold lower than the rodent LOAEL of $5\;{mg}/{kg}/\text{day}$ by the ATSDR ([@c3]). The ATSDR set the human tolerable daily intake at $0.005\;{mg}/{kg}/\text{day}$ based on the rodent LOAEL. Human exposure to DBT via leaching from PVC water pipes was estimated at about 100-fold lower levels, $34\,\text{ng}/{kg}/\text{day}$ ([@c18]). It is noteworthy that this was based exclusively on estimated exposure from a single source but did not consider possible exposure from other sources, such as house dust, food contamination, and medical devices, etc. Therefore, human daily exposure to DBT may be higher than this estimate. To the best of our knowledge, human biomonitoring for DBT (or of any organotin) levels is not currently being conducted by any public health agency.

Conclusion {#s5}
==========

In this study, we demonstrated that DBT acted as an obesogen both *in vitro* and *in vivo*. Adipogenic differentiation in exposed human and mouse MSCs exhibited increased lipid storage in cells in a $\text{PPAR}\gamma\text{-dependent}$ manner. *In vivo* perinatal exposure of mice to environmentally relevant doses of DBT led to increased fat storage, glucose intolerance, and increased leptin levels in males, conditions indicative of a prediabetic phenotype. These results support the hypothesis that at least one obesogen, DBT, has the potential to interact with diet to induce a prediabetic condition. To reduce and reverse the growing epidemics of obesity and related disorders such as type 2 diabetes, we suggest that human exposures to organotins such as DBT and TBT should be measured systematically to understand how they contribute to the obesity epidemic and to identify levels and sources of exposure that could be reduced or eliminated in the future.

Supplemental Material
=====================

###### 

Click here for additional data file.

This work was supported by grants from NIH (ES023316, ES015849, ES015849-03S1). The authors thank all members of the Blumberg laboratory for their technical assistance and Dr. Rosh Chandraratna (IO Therapeutics, Santa Ana, CA) for a gift of IRX194204, and Dr. Roland Schuele (University of Freiburg, Germany) for a gift of the plasmid $\text{pSG}5\text{-mRXR}\alpha$.
